Millar Granted Exclusive Rights to Endotronix MEMS Sensor Technology in the Neurosurgical Care Market

Millar Granted Exclusive Rights to Endotronix MEMS Sensor Technology in the Neurosurgical Care Market

HOUSTON, March 17, 2017 /PRNewswire/ -- Today Millar, Inc., a medical device and OEM solutions company, and Endotronix, Inc., a digital health medtech company providing solutions for patients who suffer from advanced heart failure, are pleased to announce an agreement that grants Millar exclusive rights to the Endotronix wireless MEMS sensor technology for sales and development in the neurosurgical care market. The technology will be developed for at-home monitoring of intracranial pressure (ICP) for patients suffering from hydrocephalus to improve quality of life and reduce treatment costs.

"The implantable Endotronix sensor technology is an excellent complement to our existing catheter-based MEMS pressure sensor offerings. We have a 25-year history in sensor-enabled catheters for monitoring ICP following a traumatic brain injury," stated Simon Malpas, CSO, Millar. "More recently we have focused on implantable MEMS platforms to expand the utility for neurosurgeons and medical researchers. We believe the Endotronix technology can provide reliable, real-time ICP measurements that will positively impact patient outcomes."

Millar is a leading manufacturer of high-fidelity pressure sensors for the medical device, cardiovascular and basic science markets. The company's MEMS pressure sensors have been recognized as the gold standard for pressure measurement and are utilized daily in cardiac cath labs, pharmaceutical discovery, and research laboratories around the world. Millar sensor-enabled catheters have played a crucial role in advancing scientific understanding in the life sciences while also providing the most accurate pressure measurements for the validation of new life-saving drug compounds and innovative medical devices.

"We believe the core sensor technology and patient management platform used in the Endotronix Cordella™ Heart Failure System has applications beyond the cardiovascular space to provide clinical-grade vital sign monitoring with improved patient-physician communication," commented Harry Rowland, CEO, Endotronix. "We are thrilled to partner with Millar which has an impressive history in the neurosurgical care market."

This announcement is the latest example of the Millar's ongoing strategic shift towards becoming an active OEM supplier of novel technologies, including its MEMS pressure sensors and wireless power platform, to the medical device community.  It comes on the heels of the launch of its new Millar OEM Solutions brand that is being highlighted in Booth 1430 at the American College of Cardiology's 66th Annual Scientific Session & Expo in Washington, DC March 17 – 19th. Expect more news from the company in the following months.

About Millar, Inc.
Since 1969, Millar, Inc. has led the development of catheter-based, solid-state pressure sensors and is known worldwide as the leader in sensors that advance medical understanding. Millar OEM serves the medical device and life sciences industries through our MEMS pressure sensors, ISO 13485 precision manufacturing, and wireless power technology, resulting in cost savings and rapid time to market for device integration.

About Endotronix, Inc.
Endotronix, Inc., a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The company's solution, the Cordella™ Heart Failure System, includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. Learn more at www.endotronix.com.